TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
Comments (0)Posts tagged: oncogenex
Comments (0)
Teva Pharmaceuticals, OncoGenex initiates SYNERGY Phase 3 trial to evaluate custirsen
Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).
OncoGenex Pharmaceuticals, Inc. – Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
BOTHELL, WA and VANCOUVER, Sept. 22 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate ...
OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
BOTHELL, WA and VANCOUVER , June 3 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that Scott Cormack , OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference on June 10 at 10:40 a.m. ...
OncoGenex Reports First Quarter Financial Results
Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA , and ...
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex’ Late Stage Innovative Treatment for Multiple Oncology Indications
-- Phase III trials of OGX-011 in first- and second-line advanced prostate cancer and non-small cell lung cancer, expected to begin in 2010 and early 2011 -- -- Significantly strengthens Teva's oncology offerings with novel therapeutic designed to target resistance to cancer treatments ...
Isis Pharmaceuticals to Receive $10 Million From OncoGenex’ License of OGX-011 to Teva
CARLSBAD, Calif., Dec. 21 /- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a ...
OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
BOTHELL, WA and VANCOUVER, BC, Dec. 20 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009. A live webcast will be available through the Investor ...
OncoGenex Reports Third Quarter 2009 Financial Results
Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER Nov. 5 / OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI ) today reported unaudited financial results for the third quarter and nine months ended ...
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
BOTHELL, WA and VANCOUVER Nov. 2 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon to ...